Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/07/26	$5.650	+11.88%	458,116
13/07/26	$5.050	-14.12%	476,169
10/07/26	$5.880	-3.13%	352,501
09/07/26	$6.070	-6.47%	600,559
08/07/26	$6.490	+9.08%	1,460,228

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 15/07/2026 +04			5-day change	1st Jan Change
5.650 ^USD	+11.88%		-5.04%	-73.10%

05-09	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
01/11/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI

Market Cap	3.02B 2.64B 2.44B 2.25B 4.24B 290B 4.32B 29.07B 11.41B 142B 11.33B 11.08B 489B	P/E 2024	-10.2x	P/E 2025	-2,351x
Enterprise Value	3.01B 2.63B 2.43B 2.25B 4.24B 289B 4.31B 29.03B 11.39B 142B 11.32B 11.07B 488B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	11.64%	Yield 2024 *	-	Yield 2025	-

05-09	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
01/11/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
31/10/25	Regencell Bioscience Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
22/09/25	Regencell Bioscience Holdings Limited(NasdaqCM:RGC) added to S&P Global BMI Index	CI
30/06/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
30/06/25	Regencell Bioscience Holdings Limited Announces Board Changes, Effective June 30, 2025	CI
25/06/25	Top Premarket Gainers	MT
23/06/25	Top Premarket Decliners	MT
20/06/25	Top Premarket Decliners	MT
18/06/25	Top Premarket Decliners	MT
17/06/25	Top Premarket Gainers	MT
17/06/25	Regencell Bioscience Extends Gains Pre-Bell Tuesday Following 276% Surge Monday	MT
16/06/25	Top Premarket Gainers	MT

06-17	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-16	RGC Holzer & Holzer, LLC Reminds Investors of the June 23, 2026 Lead Plaintiff Deadline in the Regencell Bioscience Holdings Limited Securities Class Action	NE
06-15	RGC Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-12	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-10	RGC INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026	NE

Regencell Bioscience Holdings Limited Stock

Stocks

RGC

KYG7487R1002

Biotechnology & Medical Research

Valuation: Regencell Bioscience Holdings Limited

Chart: Regencell Bioscience Holdings Limited

Latest news : Regencell Bioscience Holdings Limited

Analysts' recommendations: Regencell Bioscience Holdings Limited

Press Releases: Regencell Bioscience Holdings Limited

News in other languages: Regencell Bioscience Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Regencell Bioscience Holdings Limited

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

27/06/25	El milagro de las hierbas : esta acción sube un 20.000% en un año sin vender nada
18/02/22	La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...
18/02/22	La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...
17/02/22	Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen
17/02/22	Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días

1 day	+11.88%
1 week	-5.04%
Current month	-7.22%
1 month	-69.99%
3 months	-81.24%
6 months	-83.94%
Current year	-73.10%

1 week	4.92	6.89
1 month	4.92	17.92
Current year	4.92	69
1 year	4.92	69
3 years	0.08	83.6
5 years	0.08	83.6
10 years	0.08	83.6

Manager	Title	Age	Since
Yat-Gai Au CEO	Chief Executive Officer	54	01/01/2014
Wai Hong Chung COO	Chief Operating Officer	49	01/08/2021
Yat-Pui Au PRN	Corporate Officer/Principal	52	01/02/2023

Director	Title	Age	Since
Wai Hong Chung BRD	Director/Board Member	49	28/12/2023
Yee Wah Hui BRD	Director/Board Member	54	01/07/2021
Wing Yan Lo BRD	Director/Board Member	65	13/12/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-27	Yee Wah Hui	Issuer sale	Director	-19,000	0.0038%
05-27	Wing Yan Lo	Issuer sale	Director	-70,600	0.0143%
03-18	Yat-Gai Au	Other	Chief Executive Officer	437,896,116	88.5553%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+11.88%	-5.04%	-61.51%	+883.46%	2.8B
LONZA GROUP AG	-0.22%	+1.19%	+2.87%	+7.13%	50.35B
REVOLUTION MEDICINES, INC.	+0.55%	-2.88%	+382.07%	+593.81%	39.32B
IQVIA HOLDINGS INC.	+0.13%	-0.19%	+29.79%	-6.00%	34.69B
BEONE MEDICINES AG	+0.86%	-0.78%	+21.58%	+56.15%	34.08B
CELLTRION, INC.	-1.31%	-3.03%	+2.51%	+25.24%	26.63B
ASCENDIS PHARMA A/S	+0.13%	-0.52%	-	-	16.49B
MEDPACE HOLDINGS, INC.	+1.13%	-1.85%	+67.36%	+120.46%	15.31B
EUROFINS SCIENTIFIC SE	-0.17%	+2.71%	+14.27%	+17.26%	13.8B
ICON PUBLIC LIMITED COMPANY	+1.13%	-0.44%	+12.34%	-31.79%	12.87B
Average	+1.41%	-1.25%	+52.36%	+185.08%	24.63B
Weighted average by Cap.	+0.30%	-0.78%	+79.27%	+131.54%

	2024	2025
Net sales	-	-
Net income	-4.3M -3.76M -3.48M -3.21M -6.05M -413M -6.16M -41.44M -16.26M -202M -16.16M -15.8M -697M	-3.58M -3.13M -2.9M -2.68M -5.04M -344M -5.13M -34.53M -13.55M -169M -13.46M -13.17M -580M
Net Debt	-7.88M -6.88M -6.36M -5.88M -11.07M -756M -11.27M -75.87M -29.77M -370M -29.58M -28.93M -1.28B	-4.35M -3.8M -3.52M -3.25M -6.12M -418M -6.23M -41.93M -16.45M -205M -16.35M -15.99M -705M